always looking for a good trade
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, the filing is about the old management after all. What we would like to see is any kind of information about the efforts that have been made the by the actual CEO to add value to the shareholders.
I agree is cheap, but based on what?...For me they have all the chances to do good business contracts and thats why have 30million of TGGI shares so far.
In this pennies it is required updates. With good new buyers will come and share price will move higher.
EFOI
"Founded in 1985, Energy Focus is a global leader in the development, manufacture, and marketing of energy efficient lighting solutions for the commercial, retail, grocery, military, museum, and pool and spa markets.
Our products
Our products span a range of environments and applications, including down lighting, accent lighting, display lighting, outdoor and underwater lighting, decorative fixtures and specialty applications. "
http://www.energyfocusinc.com/about
The core business is not much different from TGGI so why don´t a merger between them.
Of course TGGI is much smaller than EFOI, but who knows...
I also would like to see any kind of guidance.
Razor1965 send me a PM with your e-mail and i will answer you.
"Adequate cash flow" it was also what i like more. It seems that this CEO knows what to do.
Nice to see that the "stop" was removed.
But the annual report as expected doesn´t say much about the future, but it was nice to see the actual CEO work on this.
Waiting for more information about TGGI business plans, but still confident about them.
Regards
This should move much higher as we approach June 8.
Did you see the 8-K? Excellent.
NICE NEWS SEE THE 8-K. No more ATM
"In response to shareholder feedback and concerns, on May 18, 2012, the Company notified MLV & Co. LLC ( “ MLV ” ) that it was
terminating the At Market Issuance Sales Agreement (the “ Sales Agreement ” ) between the Company and MLV dated as of May 9, 2012.
The termination is effective as of May 28, 2012. No shares were sold under the Sales Agreement and the Company does not intend to sell any
shares under the Sales Agreement prior to the termination date."
http://ecte.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=y_fBFOXW68Fu2jS&ID=8630537
Subject: ECTE: Q1 In Line, ATM Agreement a New Overhang, ADA an Upcoming Catalyst, Maintain Estimates, Rating
Essentially in-line Q1 results, no change to estimates: Echo Therapeutics filed its 10-Q for Q1 2012, reporting a net loss of ($0.08) on revenue of $31,000 compared to our estimates for an ($0.08) net loss and $31,000 in revenue, and consensus of ($0.07) and $84,000. No change to our forward estimates, rating, or price target.
New financing agreement announced, could be overhang on stock: The Company entered into an At The Market (ATM) issuance sales agreement with an investment bank, which enables the company to issue and sell up to $20 million in common stock at the company's option. The sales agreement will terminate upon the earlier of the sale of all common stock subject to the sales agreement or termination of the sales agreement by the company or the bank. To date, no shares have been sold under the sales agreement. The agreement provides the company with financing flexibility as it continues to move its products through development. However, the ATM agreement vehicle resembles an equity line, and as such will be seen as an overhang on the stock by investors who are worried about possible dilution, which could serve to limit the near-term upside for the shares.
Upcoming catalysts: Completion of the last of three pre-IDE studies for the Symphony transdermal continuous glucose monitor sensor (tCGMS) is still expected in Q2 2012. After successfully testing the device in healthy volunteers and diabetics, the third study is evaluating Symphony in hospitalized critical care patients. Echo recently announced positive data from one of the two sites involved in this third study, showing that the Symphony achieved a mean absolute relative difference (MARD), or error rate of 12.3%. This error rate is consistent with the expected recommendation that accuracy for intermittent blood glucose measurements in critically ill patients should be less than 12.5% error, and compares favorably with the proposed 15% standard being proposed for whole blood glucose meters. When completed, this study could be a near-term catalyst that validates an important component in the company’s commercialization strategy. Assuming a successful completion to the pre-IDE studies and final agreement with the FDA on trial protocol, a 200-patient pivotal trial for Symphony could commence by mid-2012. Submission of a PMA Supplement could take place by the end of 2012.
Data from the first two arms of the pre-IDE study to be presented at ADA. Detailed data from the first two arms of the Symphony pre-IDE study of Type-1 and Type-2 diabetics.are scheduled to be presented at the annual meeting of the American Diabetes Association on Friday, June 8, followed by an investor meeting that evening.
Maintain rating, price target: We estimate the stock is worth approximately $4.00 per share based on our 2017 revenue estimate of $93 million discounted at 20%, which assumes the shares trade in line with the comp group median of 7.4x and that the company has approximately 80 million shares outstanding in 2017. We do not include revenue from a consumer product in our valuation estimates
Is today a bottom? The 52 wk low is 1,62...interesting to see how this will go next couple of days.
Ya. Even though buying a litle more at this low point.
Very low volume in this downside movement. I have bought a litle more at this levels.
I like what i have read today from Northland Securities:
"Maintain rating, price target: We estimate the stock is worth approximately $4.00 per share based on our 2017 revenue estimate of $93 million discounted at 20%, which assumes the shares trade in line with the comp group median of 7.4x and that the company has approximately 80 million shares outstanding in 2017. We do not include revenue from a consumer product in our valuation estimates."
Can you post this on $Heff board.
Thanks
I saw now that Heff has this stock to.lol. Nice
Where is the people in this board?lol...time to acumulate.
LEVEL II Update
BID 1,86 ASK 1,88
BID 1,85 ASK 1,93
BID 1,83 ASK 1,95
BID 1,89 ASK 2,04
Lol, this is a small cap not very well know in market.
But what i like in this company is that their devices are going to be used by diabetic people in order to improve their lifes.
And what is the size of this market in USA and Europe...?Huge.
When new investors realize this, the stock price should go up consistently.
Of course, i think late this year they will need a litle more money to go to FDA approaval. But if the share price already be around $3 they won´t sell many shares.
Regards
Stock Price $3,5 in June...if they release strong results we will see.
The small float is excellent for ECTE produce strong movements with just 500k to 1Million.
I like the ECTE profile. All the work that have been done so far are very organized and consistent.
In every study they show that their products are safe and produce very good results.
This should move higher as we approach June. Accumulating time now.
Already with 10K.
AGREE!
Price Targets Update ECTE:
Northland Securities: $4 Outperform
Feltl&CO.: $2.34 Buy
LifeTech Capital: $5 Speculative Strong Buy
Average: $ 3,78. Well Above 1,85 now
Regards
until that, the company has the time to bring value to the shareholders and regain compliance with nasdaq rules.
I believe they will.
Interesting. Nice post.
EFOI buying TGGI it will be very interesting.
Note: There is no news, just my opinion.
We have 0,04% of the company.lol
In my opinion June will be the beginning of something big:
"Data from that study demonstrated that Symphony reliably monitored glucose levels in an intensive care unit. Results from the second study are expected in the second quarter."
I bought more at this levels. This is down with low volume and i am not worry with that.
The size of ECTE products are huge in the diabetic market.
And in last year they have been working well in order to put their products into the market.
Don´t Worry, Price Target $4 to $6 with positive news in June and with the achievement of next milestones.
The low float will help this fly quickly.
Level II is thin. Easily goes to $2 area and more with good news as we approach June.
Hi, Still Holding 30Million!
Regards
ECTE doing very well. June will be very important for the company and for the shareholders.
Now is time to buy as we approach June! With a small float this could go to $4.
Are you expecting a pull back to 0,0025?
I think the 50 day average and the 200 day averge (0,0019) will act as a support.
Ok thank you
Hi, I have three questions, before buy:
- Who has the float? After all is about 1billion shares.
- There is any kind of non-dilution or what are the rate that company are selling shares?
- The company has debt? Positive ebitda foi itself it´s good, but could hid debt, etc.
Thank in advance.
Nice point. Agree.
Thank you. Solid information.
Yes it is and what is necessary is an update about their business plans.